Salix Coronary Plaque vs Autoplaque

Direct competitors — feature-level head-to-head below. Comparability 90/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Artrya Limited
VS
by Cedars-Sinai Medical Center: AIM

AI Verdict

Both tools offer FDA-cleared AI-powered quantitative analysis of coronary plaque and luminal stenoses from CCTA images, making them direct competitors for aiding in the diagnosis and risk assessment of coronary artery disease. The primary distinction lies in their deployment, with Tool A being cloud-based for near real-time, point-of-care assessment, and Tool B being a workstation-based application focused on comprehensive post-processing analysis for heart attack risk prediction.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your clinical workflow prioritizes near real-time, point-of-care assessment of CCTA scans for rapid diagnosis and immediate treatment planning. Its web-based, cloud deployment and automated report generation are ideal for environments needing efficient, integrated workflow management and quick turnaround for coronary artery disease assessment.

View Salix Coronary Plaque →

Choose Autoplaque if…

Choose Autoplaque if your practice requires a workstation-based solution for detailed, quantitative post-processing and analysis of coronary plaques and stenoses. This tool is well-suited for clinicians who need to meticulously review and edit automated segmentations, perform precise measurements, and utilize advanced multiplanar reformatting views for comprehensive assessment and potentially research-oriented applications.

View Autoplaque →

When choosing between Salix Coronary Plaque and Autoplaque, physicians should consider their workflow and specific needs for CCTA analysis. Salix Coronary Plaque, a web-based solution, excels in providing near real-time, point-of-care assessments, making it ideal for practices prioritizing rapid diagnostics and integrated workflow management. It offers comprehensive plaque characterization, including high-risk features and automated report generation, which can streamline the diagnostic process. The per-scan reimbursement model may also be a practical consideration for some practices.

Autoplaque, on the other hand, is a workstation-based software, offering robust quantitative analysis of coronary plaques and luminal stenoses. Its deployment on Windows or Mac platforms provides flexibility for practices preferring on-premise solutions and direct control over their post-processing applications. While both tools are FDA-cleared and provide AI-powered plaque analysis, the key practical difference lies in their deployment and workflow integration: Salix is cloud-based and geared for rapid, integrated assessments, while Autoplaque is a workstation-based tool for in-depth, clinician-reviewable analysis. Physicians seeking a quick, integrated, and cloud-accessible solution for CCTA analysis may lean towards Salix Coronary Plaque. Conversely, those who prefer a workstation-based application with detailed, editable segmentation and analysis capabilities might find Autoplaque a more suitable choice.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Salix Coronary Plaque Autoplaque
Pricing Contact for pricing Not disclosed
Deployment Cloud Workstation-based software, runs on Windows or Mac computer platforms
FDA Status Yes AI-estimated 1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Salix Coronary Plaque

Tool A is a web-based, cloud-deployed software, which generally offers greater accessibility and easier integration into existing healthcare IT infrastructure compared to workstation-based software. Its features like integrated workflow management and automated report generation further enhance a streamlined user experience.

Clinical Value

Salix Coronary Plaque

Both tools are FDA-cleared and provide quantitative analysis of coronary plaques and stenosis. However, Tool A explicitly lists the identification of specific 'high-risk plaque features' (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign) and 'calcium scoring,' offering a more detailed and comprehensive diagnostic output crucial for precise risk stratification and treatment planning.

Pricing & Value

Salix Coronary Plaque

Tool A provides a transparent pricing model based on a per-scan assessment and references a US CPT reimbursement rate of US$950 per assessment. This clarity allows potential users to better evaluate the financial implications and value proposition, whereas Tool B has not disclosed any pricing information.

Enterprise Readiness

Salix Coronary Plaque

Tool A's cloud-based, web-accessible deployment and integrated workflow management make it inherently more scalable and easier to manage within an enterprise environment. Workstation-based software like Tool B can pose challenges for widespread deployment, maintenance, and centralized management across a large organization.

Innovation

Salix Coronary Plaque

While both leverage AI for plaque analysis, Tool A demonstrates a slight edge in innovation by emphasizing 'near real-time, point-of-care assessment' and explicitly detailing the identification of specific 'high-risk plaque features.' This focus on immediate clinical utility and advanced plaque characterization represents a more forward-thinking approach.

Support & Docs

Salix Coronary Plaque

Both tools imply the existence of user manuals and the necessity for user training. However, Tool A (Artrya Salix) provides more explicit evidence of a comprehensive support and documentation framework through its numerous certifications, including ISO 9001, ISO 13485, ISO 27001, HIPAA, and GDPR, which are indicative of well-defined processes for quality, security, and user support.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Salix Coronary Plaque Autoplaque
Product Name Salix Coronary Plaque Autoplaque
Company Artrya Limited Cedars-Sinai Medical Center: AIM
Core Analysis Functionality AI-driven, web-based software for near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images
Specific Plaque Features Identified Detection and quantification of coronary plaque (atherosclerosis), identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), stenosis assessment, quantification of calcifications (calcium scoring) Detection and characterization of coronary artery plaque, measurement of luminal stenoses, automated vessel, plaque, and lumen segmentation
Workflow & Output Features Integrated workflow management, automated report generation (editable) Workstation-based post-processing application, automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician), review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views, measurement of vessel diameter and area

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and Autoplaque.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Salix Coronary Plaque explicitly identifies high-risk plaque features such as low-attenuation plaque, spotty calcification, positive remodeling, and the napkin-ring sign. Autoplaque offers AI-powered quantitative analysis and characterization of coronary artery plaque, but does not list these specific high-risk features in the provided details.
Salix Coronary Plaque offers near real-time, point-of-care assessment with integrated workflow management and automated, editable report generation, with assessments available in under ten minutes. Autoplaque is a workstation-based post-processing application that includes automated segmentation reviewable and editable by clinicians.
Salix Coronary Plaque is developed by Artrya Limited, an AI-driven MedTech company. Autoplaque is developed by Cedars-Sinai Medical Center: AIM, an academic medical center.
Both tools allow for clinician review and editing. Salix Coronary Plaque generates automated reports that are editable. Autoplaque provides automated vessel, plaque, and lumen segmentation that is reviewable and editable by the clinician.
AI Tool Finder
AI-powered search. Results may not be comprehensive.